Introduction
camptothecin derivative, is mainly transported into liver by solute carriers and metabolized into ametabolite, SN-38, by a carboxylesterase [6] . In turn, SN-38 is glucuronidated by uridinediphosphate (UDP)-glucuronosyltransferases (UGTs) to an inactive form, SN-38G. Lower glucuronidation rates lead to higher SN-38 concentrations, resulting in irinotecan-induced severe toxicity [7] . Diarrhea and neutropenia are the most common side effects of irinotecan-based chemotherapy, limiting its application [8] . Recent studies have confirmed thatUDP UGT 1A1 play a vital role in the process of glucuronidation [9, 10] .
The UGT1A1*28 polymorphism contains an extra TA repeat in the 5′-promoter region, whose mutant genotype is A(TA)7TAA (TA7/7) and has a wide genotype of A(TA) 6 TAA (TA6/6). Toffoli et al. [11] found that UGT1A1*28 TA7/TA7 genotype is related to a lower glucuronidation ratio. Previous studies investigated the relationship of UGT1A1*28 with neutropenia and diarrhea and have shown conflicting results. TA6/6 was reported to be a main predictive factor for diarrhea in a study of 56 advanced colorectal carcinoma (CRC) [12] . In contrast, some studies found that patients with the TA6/7 or TA7/7 genotypes are more inclined to suffer severe neutropenia and diarrhea [13] [14] [15] [16] . However, no correlation was defined between the UGT1A1*28 polymorphism and neutropenia according to data from Hirata et al. [17] and Ferraldeschi et al. [18] .
To clarify the predictive value of the UGT1A1*28 polymorphism in patients receiving irinotecan-based chemotherapy, we conducted this study to investigate the impact of the UGT1A1*28 polymorphism on tumor response and the common toxicities, diarrhea and neutropenia.
Materials and methods

Publication Search
Studies were selected by retrieving the Web of Science, PubMed, CNKI, and WanFang databases, up to June 2016. Similar keywords were used in different databases:
"UGT1A1*28" and "diarrhea," "UGT1A1*28" and "neutropenia," "UGT1A1*28" and "response,"
"UGT1A1*28" and "irinotecan," "UGT1A1*28" and "CPT-11," and related terms. No language restrictions were applied. All qualified studies were searched and a cross search was also used to identify the remaining relevant studies. When overlapping data exist in different reports, the most complete article was included. Disagreements between two authors will be settled by discussion and consensus.
Selection Criteria
Studies were included if they fulfilled the following criteria: (a) clinical trials; (b) evaluated the association of the UGT1A1*28 polymorphism with irinotecan-induced toxicities and chemotherapeutic effect; and (c) contained key information about the number of patients who have severe diarrhea, neutropenia and response to chemotherapy or not. Duplicate studies, review articles, letters, non-original studies, or case reports were excluded.
Data Extraction
Detailed information of included studies had been extracted and recorded in a standardized table by two reviewers. The following information was recorded: first author's surname, year of publication, ethnicity, cancer subtype, methods of mutation detection, number of patients with and without response, severe diarrhea and neutropenia, genotypes were extracted. If these data were not reported, items were marked "NR" (not reported).
Data Synthesis
This meta-analysis was conducted according to the PRISMA guidelines [19] . We used the Newcastle-Ottawa-Scale (NOS) to assess the qualities of including studies and calculated the combined odd ratios (ORs) and 95% confidence intervals (CIs) to evaluate the strength of relationship between the UGT1A1*28 polymorphism and irinotecan-induced diarrhea or neutropenia under the four models (TA6/7 vs. TA6/6, TA7/7 vs. TA6/6, TA6/7+TA7/7 vs. TA6/6, and TA7/7 vs. TA6/6+TA6/7) [20] . The association between tumor response and the UGT1A1*28 polymorphism was calculated only in the dominant model (TA6/7+TA7/7 vs. TA6/6). Pooled ORs were tested by the Z test, and a P value <0.05 was considered significant. Chi-square test and Q test were used to examine the heterogeneity among the studies. We also performed stratified analysis depending on tumor types (advanced gastric cancer, metastatic non-small cell lung cancer, metastatic colorectal cancer, or others), ethnicity (Asian, Caucasian or mixed people) and study design (retrospective or prospective study). Publication bias were determined by Egger's and Begg's tests [21, 22] . Specific methods are described in our pervious study [23] . A trim and fill method of adjusting for publication bias was carried out when the P value of Egger's test was less than 0.05 [24] . Trial sequential analysis (TSA) was conducted to calculate the required sample size to get a robust conclusion [20] . When P values of two-sided comparisons were less than 0.05, we considered the difference was significant. We performed all the statistical calculations by STATA 12.0 (StataCorp LP, College Station, TX, USA).
Results
Characteristics of the Studies Included
As shown in Figure 1 , we performed the primary literature retrieval using the PubMed, Web of Science, Wanfang, and CNKI databases by the end of June 2016. First, 307 articles were included and 119 articles were excluded after searching for duplicates. Second, we read the titles and abstracts and excluded 78 articles because they were letters, case reports, reviews or reporting about other polymorphisms. Finally, after reading the full-text of all articles, 53 articles were excluded due to lacking of useful data or evaluation about other toxicities and 58 studies from 57 articles including 6087 patients with cancer were found to meet the inclusion criteria. Among these studies, 16 studies investigated the associations in Caucasians [11-15, 18, 25-35] , 40 in Asians [3, 9, 16, 17, , and two in mixed population or not reported [63, 64] . All studies were retrospective or prospective studies, including 29 metastatic colorectal cancer (mCRC) studies, five metastatic non-small cell lung cancer (mNSCLC), three advanced gastric cancer (GC) studies, two SCLC studies, and two advanced esophageal cancer studies and others. Table 1 summarized the basic information of the included studies.
Meta-Analysis of UGT1A1*28 Polymorphism and Severe Diarrhea
There were 44 studies of 4868 patients to evaluate the relationships between the UGT1A1*28 polymorphism and irinotecan-induced severe diarrhea. As shown in Table 2 and Figure 2, Stratified analysis according to cancer type was also carried out in this study. Individuals with mCRC carrying the TA7/7 or TA6/7 genotypes had a higher risk of getting diarrhea after irinotecan-based chemotherapy compared with the TA6/6 genotype (TA6/7 vs. TA6/6: OR = 1.60, 95%CI = 1.11-2.31, P = 0.011; TA7/7 vs. TA6/6: OR = 3.53, 95%CI = 1.54-8.09, P = 0.003). The same risk was also seen in SCLC patients (TA6/7+TA7/7 vs. TA6/6: OR = 3.95, 95%CI = 1.42-11.01, P = 0.009; TA7/7 vs. TA6/6+TA6/7: OR = 19.90, 95%CI = 2.57-154.1, P = 0.004).
Meta-Analysis of UGT1A1*28 Polymorphism and Severe Neutropenia
The relationships of the UGT1A1*28 polymorphism with irinotecan-induced severe neutropenia risk were investigated in 49 studies of 5232 patients. The UGT1A1*28 polymorphism was significantly related to an increased severe neutropenia incidence (Table 3 and Caucasians and Asians with at least one TA7 allele had a higher risk of neutropenia (Caucasians: TA6/7 or TA7/7 vs. TA6/6: OR = 1.84 and 5.67; Asians: TA6/7 or TA7/7 vs. TA6/6: OR = 1.56 and 4.77). In the analysis stratified by cancer type and study design, an association was also found in retrospective and prospective designs, with mCRC patients having the TA7/7 and TA6/7 genotypes (TA6/7 or TA7/7 vs. TA6/6: OR = 1.76 and 5.07) and solid tumor patients with the TA7/7 genotype (TA7/7 vs. TA6/6 or TA6/6+6/7: OR = 7.66 and 6.68). 
Meta-Analysis of UGT1A1*28 Polymorphism and Response
Eighteen studies with 2024 patients were assessed to determine the association of the UGT1A1*28 polymorphism with tumor response to irinotecan-based chemotherapy (Table 4 and Figure  4) . A partial or complete remission was grouped as a response, while stable tumor or progression was considered no response. A response occurred in patients with at least one mutation allele but not in patients with the wide genotype (TA6/7+TA7/7 vs. TA6/6: OR = 1.20, 95%CI = 1.07-1.34, P = 0.016). The association was significant in Caucasians (OR = 1.23, 95%CI = 1.06-1.42, P = 0.006), retrospective study designs (OR = 1.54, 95%CI = 1.06-2.23, P = 0.022), and mCRC patients (OR = 1.24, 95%CI = 1.05-1.48, P = 0.014).
Heterogeneity Analysis
There was high heterogeneity among studies evaluating severe diarrhea under the homozygous and recessive comparisons (TA7/7 vs. TA6/6: P = 0.007, I 2 = 51.7%; TA7/7 vs. TA6/6+TA6/7: P<0.001, I 2 = 57.6%). We performed meta-regression to explore the sources of heterogeneity. The data indicated that ethnicity and year of publication accounted for 76% and 26% of heterogeneity under the homozygous model and 54% and 41% under the recessive model, respectively (data not shown). There was high heterogeneity among studies of neutropenia under recessive comparison (P<0.001, I 2 = 60.7%). The meta-regression results only revealed that the number of patients represented 25% of the heterogeneity and no other factors were found (data not shown). 
Publication Bias
To detect publication bias in studies that evaluated diarrhea and neutropenia, we performed the Begg and Egger tests ( Table 5 ). As shown in Table  5 , publication bias was found only among the studies of neutropenia under the dominant model (P = 0.027). Next, a trim and fill method was applied and the results (OR = 1.80, 95%CI = 1.37-2.36, P<0.001) showed no statistical difference compared from the results described above (OR = 2.15, 95%CI = 1.71-2.70,
P<0.001).
There was also no publication bias in studies evaluating response (P = 0.082). Thus, publication bias did not appear to affect our results.
Sensitivity Analysis
Statistical analysis was conducted as described previously [23] . As shown in Figure 5 , 6, and 7, the results were not affected by omitting individual studies in this meta-analysis, indicating that our results are reliable.
Trial Sequential analysis
We used the dominant model as an example to perform the TSA, which included eighteen trials with 2024 patients. The results showed the required information size was 1078, which meant our sample size was enough to get a robust conclusion about the UGT1A1*28 polymorphism and chemotherapy response ( Figure 8 ). The required sample sizes for determining the associations between UGT1A1 and diarrhea and neutropenia under the dominant model were 763 and 1162, respectively (data were not shown). 
Discussion
A couple of meta-analyses have investigated the relationships between the UGT1A1*28 polymorphism and irinotecan-induced toxicity, severe diarrhea, and neutropenia. A study by Chen et al. in 2014 included six articles and found no statistically significant association between the UGT1A1*28 polymorphism and neutropenia in Asians (OR = 1.67, 95%CI = 0.94-2.97) [65] . Liu et al. [66] conducted a meta-analysis of 16 articles and found that mCRC patients carrying the TA7/7 genotype had a higher risk of neutropenia and diarrhea in Caucasians. In contrast to previous studies, we evaluated 58 articles including 6087 cancer patients and performed stratified analyses based on ethnicity, study design, and cancer type. Statistical difference between the UGT1A1*28 polymorphism and diarrhea was confirmed in Asian patients and mCRC patients under the five models. Individuals with at least mutation allele had a 1.71-and 5.34-fold greater risk of neutropenia than individuals carrying the wide genotype. Mutated genotypes of the UGT1A1*28 polymorphism may lower the glucuronidation rates of SN-38 and lead to greater susceptibility to severe toxicities [25, 36] .
Patients evaluated in this study, particularly mCRC patients with the TA6/7 and TA7/7 genotypes, may have severe diarrhea and neutropenia after irinotecan-induced chemotherapy. However, the UGT1A1*28 TA6/6 and TA7/7 genotypes may show an increased treatment response according to our results. In contrast to our results, Xu et al. [67] observed different clinical responses in Ugyur patients with different UGT1A1*28 polymorphism genotypes, but not in the Han population. Although the reduction of irinotecan was greater in patients with the TA7/7 or TA6/7 genotypes than the TA6/6 genotype, no difference in overall or progression-free survival between the two group patients were found by Dias et al. [68] . These results indicate that if the patients with mutant genotypes could tolerate the toxicities, irinotecan-based chemotherapy is a good choice for treatment. Additional studies of the treatment response should be carried out.
Previous meta-analyses included few than 20 studies and only focused on toxicities or chemotherapy response. In comparison with these studies, we included more research (58 studies) and investigated the associations of UGT1A1*28 polymorphism with toxicities and chemotherapy effect. We also got a novel conclusion that patients with a higher risk of chemotherapy toxicities have a tendency to better response to chemotherapy. However, there were some limitations to our study. First, the number of studies of SCLC, mNSCLC, advanced GC, solid tumors, and other cancers were limited, and thus, larger sample sizes for a single tumor are needed to validate our results. Second, high heterogeneity existed among studies related to severe neutropenia under the recessive comparison. Although the number of patients could explain 25% of the heterogeneity, other influencing factors were not identified. Third, the studies we including selected different irinotecan doses in the chemotherapies, which may lead to some bias.
Conclusions
In conclusion, we detected a significant relationship between the UGT1A1*28 polymorphism and irinotecan-induced toxicity and response to irinotecan-based chemotherapy. This polymorphism may be useful as a detective index for cancer patients receiving irinotecan-based chemotherapy.
